A Review of Modeling Checkpoint Blockade Therapy and Therapeutic Strategies in Integrative Pharmacological Approach for Metastatic Breast Cancer

Prachi Gurudiwan ^1*, Ragini Patel ¹, Urvashi Jain ¹

Quantitative Systems Pharmacology models immune processes in breast cancer, aiding personalized treatment by identifying biomarkers, resistance mechanisms, and therapeutic options

Abstract

Breast cancer remains the leading cause of mortality among women despite advancements in chemotherapy treatments. Natural chemicals are preferred for breast cancer treatment to minimize side effects and target proteins involved in processes. However, the effectiveness of checkpoints has been limited, emphasizing the need for indicators to identify individuals who will respond positively. This study introduces an empirical systems pharmacology model that considers the relationship between the system and breast cancer tissue. The model encompasses peripheral, Cancer Draining Lymph Nodes (CDLN) and tumor sections, accurately representing how immune checkpoints influence system mechanisms in CDLN and the tumor microenvironment. This model can predict responses based on measures by replicating tumor responses to checkpoint-blocking treatments. It offers a framework that can be customized for immunotherapies and their integration, with targeted molecular treatments.

Keywords: Breast Cancer, Pharmacology, Clinical Trial, Tumour

References

Abril, Y.L.N., Fernandez, I.R., Hong, J.Y., Chiang, Y.L., Kutateladze, D.A., Zhao, Q., Weiss, R.S. (2021). Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer. Oncogene. 40(9), 1644-1658.

Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 66, 15-23.

Bianchini, G., De Angelis, C., Licata, L., Gianni, L. (2022). Treatment landscape of triple-negative breast cancer—Expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19(2), 91-113.

Brett, J.O., Spring, L.M., Bardia, A., Wander, S.A. (2021). ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 23, 1-15.

Giaquinto, A.N., Sung, H., Miller, K.D., Kramer, J.L., Newman, L.A., Minihan, A., Siegel, R.L. (2022). Breast cancer statistics, 2022. CA: Cancer J Clin. 72(6), 524-541.

https://sbml.org/software/

Lee, D., Lee, W. Y., Jung, K., Kwon, Y. S., Kim, D., Hwang, G. S., ... & Kang, K. S. (2019). The inhibitory effect of cordycepin on the proliferation of MCF-7 breast cancer cells, and its mechanism: An investigation using network pharmacology-based analysis. Biomolecules, 9(9), 414.

Lee, H. S., Lee, I. H., Kang, K., Park, S. I., Jung, M., Yang, S. G., ... & Lee, D. Y. (2021). Network pharmacology-based dissection of the comprehensive molecular mechanisms of the herbal prescription FDY003 against estrogen receptor-positive breast cancer. Natural Product Communications, 16(9), 1934578X211044377.

Li, X. M., Li, M. T., Jiang, N., Si, Y. C., Zhu, M. M., Wu, Q. Y., ... & Yu, B. (2021). Network pharmacology-based approach to investigate the molecular targets of sinomenine for treating breast cancer. Cancer Management and Research, 1189-1204.

Li, Y., Wang, J., Lin, F., Yang, Y., & Chen, S. S. (2017). A methodology for cancer therapeutics by systems pharmacology-based analysis: a case study on breast cancer-related traditional Chinese medicines. PLoS One, 12(1), e0169363.

Mao, Y., Hao, J., Jin, Z. Q., Niu, Y. Y., Yang, X., Liu, D., ... & Wu, X. Z. (2017). Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients. Oncotarget, 8(16), 27007.

Mohanakurup, V., Parambil Gangadharan, S.M., Goel, P., Verma, D., Alshehri, S., Kashyap, R., Malakhil, B. (2022). Breast cancer detection on histopathological images using a composite dilated Backbone Network. Comput. Intell. Neurosci. 2022.

Nicoletto, R.E., Ofner III, C.M. (2022). Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol. 89(3), 285-311.

Paijens, S.T., Vledder, A., de Bruyn, M., Nijman, H.W. (2021). Tumor-infiltrating lymphocytes in the immunotherapy era. Cell. Mol. Immunol. 18(4), 842-859.

Qayoom, H., Alkhanani, M., Almilaibary, A., Alsagaby, S. A., & Mir, M. A. (2023). Mechanistic elucidation of Juglanthraquinone C targeting breast cancer: a network pharmacology-based investigation. Saudi Journal of Biological Sciences, 30(7), 103705.

Qayoom, H., Alkhanani, M., Almilaibary, A., Alsagaby, S.A., Mir, M.A. (2023). Mechanistic elucidation of Juglanthraquinone C targeting breast cancer: a network pharmacology-based investigation. Saudi J. Biol. Sci. 30(7), 103705.

Rascio, F., Pontrelli, P., Grandaliano, G. (2021). Cytotoxic T lymphocytes (CTLs) and kidney transplantation: An overview. Cytotoxic T-Cells: Methods and Protocols, 203-213.

Rathaur, P., Soni, M. N., Gelat, B., Rawal, R., Pandya, H. A., & Johar, K. (2021). Network pharmacology-based evaluation of natural compounds with paclitaxel for the treatment of metastatic breast cancer. Toxicology and Applied Pharmacology, 423, 115576.

Van Dooijeweert, C., Van Diest, P.J., Ellis, I.O. (2022). Grading of invasive breast carcinoma: the way forward. Virchows Arch. 480(1), 33-43.

Wang, H., Ma, H., Sové, R.J., Emens, L.A., Popel, A.S. (2021). Quantitative systems pharmacology model predictions for the efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. J. Immunother. Cancer. 9(2).

Wang, N., Wang, Q., Tang, H., Zhang, F., Zheng, Y., Wang, S., ... & Xie, X. (2017). Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells. Journal of Experimental & Clinical Cancer Research, 36(1), 1-19.

Wang, N., Yang, B., Zhang, X., Wang, S., Zheng, Y., Li, X., ... & Wang, Z. (2018). Network pharmacology-based validation of caveolin-1 as a key mediator of Ai Du Qing inhibition of drug resistance in breast cancer. Frontiers in Pharmacology, 9, 1106.

Wang, N., Zheng, Y., Gu, J., Cai, Y., Wang, S., Zhang, F., ... & Wang, Z. (2017). Network-pharmacology-based validation of TAMS/CXCL-1 as key mediator of XIAOPI formula preventing breast cancer development and metastasis. Scientific reports, 7(1), 14513.

Wu, H., Li, W., Hao, M., Wang, Y., Xue, L., Ju, C., Zhang, C. (2022). An epr-independent extravasation strategy: Deformable leukocytes as vehicles for improved solid tumor therapy. Adv. Drug Deliv. Rev. 187, 114380.

Zhang, Y. Z., Yang, J. Y., Wu, R. X., Fang, C., Lu, H., Li, H. C., ... & Chen, Q. J. (2021). Network pharmacology–based identification of key mechanisms of xihuang pill in the treatment of triple-negative breast cancer stem cells. Frontiers in Pharmacology, 12, 714628.

Zhang, Y.C., Zeng, P.Y., Ma, Z.Q., Xu, Z.Y., Wang, Z.K., Guo, B., Li, Z.T. (2022). A pH-responsive complex based on supramolecular organic framework for drug-resistant breast cancer therapy. Drug Deliv. 29(1), 1-9.